4th Annual Immuno-Oncology Summit, Boston, MA
St. Paul, Minn., July 1, 2016 - MD Biosciences, announces its presence at the 4th annual Immuno-Oncology Summit at the Marriott Long Wharf, Boston, MA - Aug. 29 – Sept. 2, 2016.
Britnie James, Ph.D., Director of the MD Biosciences Immunology Laboratories will present recent data on the impact of different animal supply and the microbiome in tumor progression and treatment studies. “Understanding the Impact of Animal Vendors and the Microbiome - in Tumor Progression and Treatment - in a Model of Metastatic Breast Cancer” will be presented at 10:00 am Wed., August 31.
MD Biosciences’ recent microbiome-related studies focused on animal vendor differences in the microbiome to identify any related impact in immunological and cellular functions. “We have examined whether animals from different vendors, with discrete microbiomes, would present with different disease progression and therapy responses in a murine model of metastatic breast cancer,” said Britnie James. “I will be presenting these research findings at the Immuno-Oncology Summit.”
According to Eddie Moradian, PhD, Chief Executive of MD Biosciences, “The impact of the microbiome on disease and therapy progression is becoming more evident. The microbiome may play an important role in the preclinical setting and possibly in the clinical settings as well. We hope to contribute to the understanding of the microbiome and its intricate relation to therapeutic progress with our research.”
About MD Biosciences
MD Biosciences is a discovery and clinical stage pharmaceutical and biotechnological company. Over the course of 25+ years, MD Biosciences has developed a platform based on scientific expertise and knowledge, plus proprietary methodologies. Its platform is based on a deep understanding of inflammatory and immunological pathways, as well as neurological processes leading to disease states and therapeutic approaches. This knowledge is applied to the development of novel therapeutics, diagnostics as well as medical devices. MD Biosciences develops its own pipeline of compounds, develops and provides products for life science research, operates a clinical diagnostic assays laboratory and provides selective services through its contract research arm.